Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

4,804 total articles

Lamb Weston Looks Set to Rebound — Q3 May Be the Tactical Bottom

Lamb Weston Looks Set to Rebound — Q3 May Be the Tactical Bottom

Lamb Weston (LW) has been punished after an ERP-related sales disruption and softer pricing, but underlying cash flow, reasonable valuation and improving technicals suggest fiscal Q3 weakness could be the low-risk entry for a mid-term rebound. This is a swing trade idea with entry, stop and target defined and a clear risk framework.

Argan's Beat Was the Beginning, Not the End - A Tactical Long

Argan's Beat Was the Beginning, Not the End - A Tactical Long

Argan reported a clean Q4 earnings beat driven by margin expansion and an outsized backlog tied to data-center and power projects. The stock has power behind it - a near-zero debt profile, strong free cash flow, and technical momentum - but it trades at a premium. This trade idea lays out a mid-term (45 trading days) entry, stop and target, plus th…

Abbott: Upgrade to Buy Ahead of Q1 — A Clearer Path to Rebound

Abbott: Upgrade to Buy Ahead of Q1 — A Clearer Path to Rebound

We upgrade Abbott Laboratories (ABT) to Buy ahead of Q1 results. At $103.52, the shares trade below near-term averages with a PE ~27.6, a healthy dividend yield (~2.3%), and strong free cash flow ($7.4B). Recent weakness centers on diagnostics and nutrition, but medical devices growth, a manageable balance sheet (debt/equity 0.25), and the $21B Exa…

Lumentum: AI Optics Rally Has Room to Run — A Tactical Long

Lumentum: AI Optics Rally Has Room to Run — A Tactical Long

Lumentum is squarely in the middle of an optical upgrade cycle for AI data centers. With an S&P 500 addition, a $2 billion strategic allocation from NVIDIA, and accelerating revenue and earnings prints, LITE has momentum. Valuation is rich, so the trade is a tactical long with a defined stop and multi-horizon targets.

Buy on Value: Laureate's Recovery Looks Real and Underpriced

Buy on Value: Laureate's Recovery Looks Real and Underpriced

Laureate Education ($LAUR) looks like a value compounder trading at sensible multiples after a strong enrollment-driven recovery and a renewed $100M repurchase program. With a market cap near $5.05B, free cash flow of $263.1M and an EV/EBITDA of 9.8, we set a long-term trade targeting $45 while protecting capital with a $30 stop.

Nvidia's $2B Bet Rewrites Marvell's AI Playbook

Nvidia's $2B Bet Rewrites Marvell's AI Playbook

Nvidia's announced $2 billion investment and strategic partnership with Marvell transforms Marvell from a fast-growing networking and storage ASIC vendor into a core partner for hyperscale AI infrastructure. With data-center revenue up 21% year-over-year and management guiding revenue to roughly $11 billion, Marvell has the growth profile and cash …

Abivax: Obefazimod’s Scarcity Is the Optionality — Maintain Buy

Abivax: Obefazimod’s Scarcity Is the Optionality — Maintain Buy

Abivax (ABVX) remains a compelling long idea. Obefazimod's differentiated data package, emerging anti-fibrotic signal and concentrated asset base create strategic scarcity that magnifies upside from a successful Phase 3 maintenance readout in Q2 2026 or a takeover bid. We maintain Buy: enter at $117.65, target $150.00, stop $95.00. Trade horizon: l…

Netflix: Upgrade to Buy — An Earnings-Driven Long With Conviction

Netflix: Upgrade to Buy — An Earnings-Driven Long With Conviction

We upgrade Netflix to Buy and propose an aggressive long ahead of the next earnings print. Netflix combines strong operating margins, meaningful free cash flow ($9.46B trailing), and a growing ad business that management expects to double in 2026. At $95.32 the risk/reward favors a long exposure into earnings and the post-earnings reaction, but thi…

Meta's Underrated AI Revenue Pipeline: A Re-rate Play at $582

Meta's Underrated AI Revenue Pipeline: A Re-rate Play at $582

Meta is trading at roughly $1.47T with $46.1B in free cash flow and a PE of ~24. Management's AI product stack — from ad targeting to developer APIs and AR experiences — has near-term revenue vectors that the market is underpricing. I outline a long trade with entry, stop and target plus catalysts and risks.